Trial to paid conversion is the quietest lever in a subscription business. Nobody writes threads about it because it is not glamorous, and improving it involves email rather than creative. But it compounds against every pound you will ever spend on acquisition.
On AskAVet it reached 43.92%. Alongside a $42.70 customer acquisition cost, that is what produced 9,000+ paying subscribers and $154K+ in monthly recurring revenue. Very little of it was done in the ad account.
Why the number matters more than
Run the arithmetic on 1,000 trials:
| Trial to paid | Customers | Effective cost per customer at $42.70 CAC |
|---|---|---|
| 15% | 150 | $284.67 |
| 25% | 250 | $170.80 |
| 43.92% | 439 | $97.22 |
Going from 15% to 43.92% cuts your real cost per customer by roughly two thirds. There is no media buying improvement available to you that does that. And unlike ad efficiency, it does not decay when you scale spend.
Most teams try to fix subscription economics in the ad account, because that is where the dashboards are. The economics are usually decided in the first seven days after signup.
Find the activation moment, then
Every subscription product has a moment where the user experiences the thing they signed up for. Until they hit it, they are not a customer, they are someone who filled in a form. On AskAVet that moment was the first consultation: an actual conversation with an actual licensed vet.
Trials that included one converted. Trials that did not, did not. Once that is established, the entire onboarding programme has a single job, and you stop debating what the welcome email should say.
What the lifecycle programme actually
- Welcome sequence. Not a brand introduction. A direct route to the activation moment, with the friction removed and the next step obvious.
- Platform education. Short, specific, triggered by what the user had not yet done rather than sent to everyone on day three.
- First consultation reminders. The single highest-value message in the programme, because it targets precisely the users about to churn silently.
- Renewal campaigns. Framed around what the subscriber had used, which makes the value concrete at exactly the moment it is being questioned.
- Customer success content. Ongoing reasons to come back, so the subscription stays connected to a habit rather than an intention.
Retarget by , not by page
Trial users were their own retargeting audience, separate from prospects, and segmented by where they had stalled. A user who signed up and never returned needs a different message from one who booked a consultation and is weighing up the price. Most accounts show both the same generic reminder and then conclude retargeting does not work.
The audience pools that earned their keep were website visitors, landing page abandoners, video viewers, trial users and email subscribers, each with messaging matched to the objection that stage produces.
Supply quality is a factor
Worth stating plainly, because it is easy to miss when you are looking at funnel metrics: on a marketplace, trial to paid conversion depends heavily on whether the trial experience was any good. 3,000+ verified veterinarians meant a trial user got a real consultation quickly. If they had waited two days for a reply, no email sequence would have rescued the conversion rate.
Where to start if this is your
- Identify the one action that separates converting trials from non-converting ones. It is usually obvious once you split the data, and it is rarely the action you have been optimising for.
- Rewrite onboarding so every message pushes toward that action and nothing else competes with it.
- Trigger on behaviour, not on elapsed days.
- Segment trial retargeting by stall point, and write to the objection.
- Check that the product experience during trial can actually carry the promise the ads made.
AskAVet — Parallel supply and demand systems took a veterinary telehealth marketplace to 3,000+ vets, 9,000+ subscribers and $154K+ MRR.
Read the full AskAVet case study